Stockscreener 앱 받기
9.30
10.45%
0.88
시장 영업 전:
9.24
-0.06
-0.65%
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix Stock Surges 10% Past $9 on Fresh SOL-1 Data Presentations for AXPAXLI - International Business Times Australia
Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates - Insider Monkey
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - MSN
Market Leaders: Will Ocular Therapeutix Inc stock hit new highs in YEAR - baoquankhu1.vn
Update Recap: Will Ocular Therapeutix Inc benefit from geopolitical trendsTrade Signal Summary & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning? - Sahm
Behavioral Patterns of OCUL and Institutional Flows - Stock Traders Daily
OCULAR THERAPEUTIX, INC. (OCUL) - MSN
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm
Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey
Ocular lines up April talks on wet AMD trial data and retinal disease - Stock Titan
Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Bitget
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - marketbeat.com
OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat
Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm
What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance
Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference - marketbeat.com
Ocular Therapeutix at RBC Conference: Promising AXPAXLI Data By Investing.com - Investing.com Canada
Ocular Therapeutix at RBC Conference: Promising AXPAXLI Data - Investing.com
OCUL: AXPAXLI showed phase III superiority over anti-VEGF, with strong regulatory and clinical momentum - TradingView
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Citizens reiterates Ocular Therapeutix stock rating amid litigation By Investing.com - Investing.com Canada
Citizens reiterates Ocular Therapeutix stock rating amid litigation - Investing.com
Jeffrey S. Heier, MD, Chief Scientific Officer, Ocular Therapeutix - Healio
EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - Fierce Pharma
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint sues Ocular over claims related to lead asset - MSN
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
Cantor Fitzgerald L. P. Buys Shares of 201,865 Ocular Therapeutix, Inc. $OCUL - MarketBeat
VR Adviser Reduces Ocular Therapeutix Stake in Q4 2025 | Portfolio ImpactNews and Statistics - IndexBox
1.57%
1.10%
자본화:
|
볼륨(24시간):